2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor

Insulin Receptor

Insulin Receptor

Related Products

PDF 0.56 MB

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P2093
    S961
    		Antagonist 99.66%
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
    S961
  • HY-15656S
    Ceritinib-d7
    		Inhibitor 98.00%
    Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.
    Ceritinib-d<sub>7</sub>
  • HY-P10302
    GLP-1R/GIPR agonist-1
    		Agonist
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
    GLP-1R/GIPR agonist-1
  • HY-P3584
    (Pro3) GIP, human
    		Agonist 99.79%
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human
  • HY-107207
    Kaempferol 3-neohesperidoside
    		Activator 99.68%
    Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside exhibits insulinomimetic effect on the rat soleus muscle.
    Kaempferol 3-neohesperidoside
  • HY-P3255
    DA-JC4
    		Agonist
    DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
    DA-JC4
  • HY-P5431
    Insulin receptor (1142-1153), pTyr1150
    		99.22%
    Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)
    Insulin receptor (1142-1153), pTyr1150
  • HY-P2093A
    S961 TFA
    		Antagonist
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
    S961 TFA
  • HY-P2080C
    GIP (1-30)-Myr
    		Agonist
    GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10-9-10-6 M.
    GIP (1-30)-Myr
  • HY-131514
    L-Ornithine 2-oxoglutarate
    		Activator
    L-Ornithine 2-oxoglutarate (Ornithine alpha-ketoglutarate) is a nutritional compound that is a salt of amino acids with antioxidant and anti-inflammatory effects. L-Ornithine 2-oxoglutarate stimulates the production of insulin and growth hormone, and promotes intracellular amino acid transport and protein synthesis.
    L-Ornithine 2-oxoglutarate
  • HY-112819
    Insulin levels modulator
    		Modulator 98.38%
    Insulin levels modulator (example 49) is an insulin secretagogue that can be used for the study of a disease associated with insufficient insulin production, such as type 2 diabetes.
    Insulin levels modulator
  • HY-15481
    KU14R
    		Antagonist 98.91%
    KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
    KU14R
  • HY-50866B
    NVP-AEW541 dihydrochloride
    		Inhibitor
    NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity.
    NVP-AEW541 dihydrochloride
  • HY-P991037
    Verenafusp alfa
    HY-P991037 is an INSR-targeting chimeric antibody.
    Verenafusp alfa
  • HY-142663
    OI338
    		Agonist
    OI338 is an orally available, ultralong-acting insulin analogue.
    OI338
  • HY-123547
    TLK19781
    		Activator
    TLK19781 is a non-peptide small molecule insulin receptor activator that increases the content of insulin-stimulated GLUT4 on the cell membrane and enhances the activity of insulin-stimulated glucose transport in cell and animal models of insulin resistance.
    TLK19781
  • HY-P4062
    Insulin peglispro
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.
    Insulin peglispro
  • HY-P3580
    Acetyl Gastric Inhibitory Peptide (human)
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-P10305
    Visepegenatide
    		Activator
    PB-119 is a PEGylated Exenatide. PB-119 decreases glycemic levels by improving beta-cell function and insulin resistance. PB-119 can be used for research of type 2 diabetes.
    Visepegenatide
  • HY-P10591
    Olatorepatide
    		Inhibitor
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect.
    Olatorepatide
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity